{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'addition, representatives of the sponsor may observe the conduct of any aspect of the clinical study', \"or its supporting activities both within and outside of the investigator's institution. In all instances,\", 'the confidentiality of the data must be respected.', '14.', 'ETHICAL AND REGULATORY CONSIDERATIONS', '14.1.', 'Good Clinical Practice Statement', 'It is the responsibility of both the sponsor and the investigator(s) to ensure that this clinical study', 'will be conducted in accordance with the ethical principles that have their origin in the Declaration', 'of Helsinki, and that are consistent with the ICH guidelines for GCP and applicable regulatory', 'requirements. The clinical study will be conducted in compliance with Pharmaceutical and', 'Medical Device Act, Japanese GCP, and other relevant laws in Japan.', '14.2.', 'Informed Consent', 'The principles of informed consent are described in ICH guidelines for GCP.', 'The ICF used by the investigator must be reviewed and approved by the sponsor prior to', 'submission to the appropriate IRB/EC. A copy of the IRB/EC-approved ICF and documentation', 'of approval must be provided to the sponsor before study drug will be shipped to the study site.', 'It is the responsibility of the investigator or designee (if acceptable by local regulations) to obtain', 'written informed consent from each patient prior to his/her participation in the study and after the', 'aims, methods, objectives, and potential hazards of the study have been explained to the patient in', 'language that he/she can understand. The ICF should be signed and dated by the patient and by', 'the investigator or authorized designee who reviewed the ICF with the patient.', 'Patient who can write but cannot read will have the ICF read to them before signing', 'and dating the ICF.', 'Patient who can understand but who can neither write nor read will have the ICF read', 'to them in presence of an impartial witness, who will sign and date the ICF to confirm', 'that informed consent was given.', \"The original ICF must be retained by the investigator as part of the patient's study record, and a\", 'copy of the signed ICF must be given to the patient.', 'If new safety information results in significant changes in the risk/benefit assessment, the ICF must', 'be reviewed and updated appropriately. All study patients must be informed of the new', 'information and provide their written consent if they wish to continue in the study. The original', \"signed revised ICF must be maintained in the patient's study record and a copy must be given to\", 'the patient.', '14.3.', 'Patient Confidentiality and Data Protection', 'The investigator must take all appropriate measures to ensure that the anonymity of each study', 'patient will be maintained. Patients should be identified by their initials and a patient identification', 'number, only, on CRFs or other documents submitted to the sponsor. Documents that will not be', 'submitted to the sponsor (eg, signed ICF) must be kept in strict confidence.', 'Regeneron Pharmaceuticals, Inc.', 'Page 103 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', \"The patient's and investigator's personal data, which may be included in the sponsor database, will\", 'be treated in compliance with all applicable laws and regulations. The sponsor shall take all', 'appropriate measures to safeguard and prevent access to this data by any unauthorized third party.', '14.4.', 'Institutional Review Board/Ethics Committee', 'An appropriately constituted IRB/EC, as described in ICH guidelines for GCP, must review and', 'approve:', 'The protocol, ICF, and any other materials to be provided to the subjects', '(eg, advertising) before any patient may be enrolled in the study', 'Any amendment or modification to the study protocol or ICF before implementation,', 'unless the change is necessary to eliminate an immediate hazard to the patients, in', 'which case the IRB/EC should be informed as soon as possible', 'Ongoing studies on an annual basis or at intervals appropriate to the degree of risk', 'In addition, the IRB/EC should be informed of any event likely to affect the safety of patients or', 'the continued conduct of the clinical study.', 'A copy of the IRB/EC approval letter with a current list of the IRB/EC members and their functions', 'must be received by the sponsor prior to shipment of drug supplies to the investigator. The', 'approval letter should include the study number and title, the documents reviewed, and the date of', 'the review.', 'Records of the IRB/EC review and approval of all study documents (including approval of ongoing', 'studies) must be kept on file by the investigator.', '15.', 'PROTOCOL AMENDMENTS', 'The sponsor may not implement a change in the design of the protocol or ICF without an', 'IRB/EC-approved amendment or formal notification from the sponsor in the event of', 'recommendations from the IDMC.', '16.', 'PREMATURE TERMINATION OF THE STUDY OR', 'CLOSE-OUT OF A SITE', '16.1.', 'Premature Termination of the Study', 'The sponsor has the right to terminate the study prematurely. Reasons may include efficacy,', 'safety, or futility, among others. Should the sponsor decide to terminate the study, the', 'investigator(s) will be notified in writing.', '16.2.', 'Close-out of a Site', 'The sponsor and the investigator have the right to close-out a site prematurely.', 'Regeneron Pharmaceuticals, Inc.', 'Page 104 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}